Muscle synergy analysis (MSA) is a mathematical technique that reduces the dimensionality of electromyographic (EMG) data. Used increasingly in biomechanics research, MSA requires methodological choices at each stage of the analysis. Differences in methodological steps affect the overall outcome, making it difficult to compare results across studies. We applied MSA to EMG data collected from individuals post-stroke identified as either responders (RES) or non-responders (nRES) on the basis of a critical post-treatment increase in walking speed. Importantly, no clinical or functional indicators identified differences between the cohort of RES and nRES at baseline. For this exploratory study, we selected the five highest RES and five lowest nRES available from a larger sample. Our goal was to assess how the methodological choices made before, during, and after MSA affect the ability to differentiate two groups with intrinsic physiologic differences based on MSA results. We investigated 30 variations in MSA methodology to determine which choices allowed differentiation of RES from nRES at baseline. Trial-to-trial variability in time-independent synergy vectors (SVs) and time-varying neural commands (NCs) were measured as a function of: (1) number of synergies computed; (2) EMG normalization method before MSA; (3) whether SVs were held constant across trials or allowed to vary during MSA; and (4) synergy analysis output normalization method after MSA. MSA methodology had a strong effect on our ability to differentiate RES from nRES at baseline. Across all 10 individuals and MSA variations, two synergies were needed to reach an average of 90% variance accounted for (VAF). Based on effect sizes, differences in SV and NC variability between groups were greatest using two synergies with SVs that varied from trial-to-trial. Differences in SV variability were clearest using unit magnitude per trial EMG normalization, while NC variability was less sensitive to EMG normalization method. No outcomes were greatly impacted by output normalization method. MSA variability for some, but not all, methods successfully differentiated intrinsic physiological differences inaccessible to traditional clinical or biomechanical assessments. Our results were sensitive to methodological choices, highlighting the need for disclosure of all aspects of MSA methodology in future studies.

Walking after stroke is often described as requiring excessive muscle co-contraction, yet, evidence that co-contraction is a ubiquitous motor control strategy for this population remains inconclusive. Co-contraction, the simultaneous activation of agonist and antagonist muscles, can be assessed with electromyography (EMG) but is often described qualitatively. Here, our goal is to determine if co-contraction is associated with gait impairments following stroke. Fifteen individuals with chronic stroke and nine healthy controls walked on an instrumented treadmill at self-selected speed. Surface EMGs were collected from the medial gastrocnemius (MG), soleus (SOL), and tibialis anterior (TA) of each leg. EMG envelope amplitudes were assessed in three ways: (1) no normalization, (2) normalization to the maximum value across the gait cycle, or (3) normalization to maximal M-wave. Three co-contraction indices were calculated across each agonist/antagonist muscle pair (MG/TA and SOL/TA) to assess the effect of using various metrics to quantify co-contraction. Two factor ANOVAs were used to compare effects of group and normalization for each metric. Co-contraction during the terminal stance (TSt) phase of gait is not different between healthy controls and the paretic leg of individuals post-stroke, regardless of the metric used to quantify co-contraction. Interestingly, co-contraction was similar between M-max and non-normalized EMG; however, normalization does not impact the ability to resolve group differences. While a modest correlation is revealed between the amount of TSt co-contraction and walking speed, the relationship is not sufficiently strong to motivate further exploration of a causal link between co-contraction and walking function after stroke. Co-contraction does not appear to be a common strategy employed by individuals after stroke. We recommend exploration of alternative EMG analysis approaches in an effort to learn more about the causal mechanisms of gait impairment following stroke.

No abstract

Stroke survivors often exhibit gait dysfunction which compromises self-efficacy and quality of life. Muscle Synergy Analysis (MSA), derived from electromyography (EMG), has been argued as a method to quantify the complexity of descending motor commands and serve as a direct correlate of neural function. However, controversy remains regarding this interpretation, specifically attribution of MSA as a neuromarker. Here we sought to determine the relationship between MSA and accepted neurophysiological parameters of motor efficacy in healthy controls, high (HFH), and low (LFH) functioning stroke survivors. Surface EMG was collected from twenty-four participants while walking at their self-selected speed. Concurrently, transcranial magnetic stimulation (TMS) was administered, during walking, to elicit motor evoked potentials (MEPs) in the plantarflexor muscles during the pre-swing phase of gait. MSA was able to differentiate control and LFH individuals. Conversely, motor neurophysiological parameters, including soleus MEP area, revealed that MEP latency differentiated control and HFH individuals. Significant correlations were revealed between MSA and motor neurophysiological parameters adding evidence to our understanding of MSA as a correlate of neural function and highlighting the utility of combining MSA with other relevant outcomes to aid interpretation of this analysis technique.